FUNDING
Key Metrics
Total funding
$290M
As of Jul 31, 2026Value Add Pulse research
Company Snapshot
Flare Therapeutics is a Biotech company, based in Cambridge, Massachusetts, founded 2021. Total funding $290M (As of Jul 31, 2026).
Recent changes
- Jul 31, 2026Jul 31, 2026First reported total funding: $290M Value Add Pulse enrichment
- Jul 1, 2026Jul 1, 2026Raised $85M Series C BioWorld
- Jun 30, 2026Jun 30, 2026Raised $85M Series C GlobeNewswire
- Jun 30, 2026Jun 30, 2026New investor: Third Rock Ventures GlobeNewswire
- Jun 30, 2026Jun 30, 2026New investor: Nextech Invest GlobeNewswire
Earlier changes (7)
- Jun 30, 2026Jun 30, 2026New investor: Casdin Capital GlobeNewswire
- Jun 30, 2026Jun 30, 2026New investor: Invus GlobeNewswire
- Jun 30, 2026Jun 30, 2026New investor: Boxer Capital GlobeNewswire
- Jun 30, 2026Jun 30, 2026New investor: Pfizer Ventures GlobeNewswire
- Jun 30, 2026Jun 30, 2026New investor: Eli Lilly GlobeNewswire
- Jun 30, 2026Jun 30, 2026New investor: GordonMD Global Investments GlobeNewswire
- Jun 30, 2026Jun 30, 2026Flare Therapeutics Raises $85M, Names New CEO Pulse story
Funding History
2 events · sources dated per row| Date | Event | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| Jul 1, 2026 | Series C | $85M | — | BioWorld | |
| Jun 30, 2026 | Series C | $85M | — | Third Rock VenturesNextech InvestPfizer VenturesEli LillyBoxer CapitalGordonMD Global InvestmentsInvusCasdin CapitalNovartisAgent CapitalEventide Asset Management outlined = lead | Pulse story |
Investors
Latest Pulse
- Jul 5, 2026Biotech VCs Are Betting Big on Single Clinical TrialsCelea Therapeutics' $180M round, Beeline Medicine's $126.3M raise and Flare Therapeutics' $85M financing show late-stage biotech investors concentrating capital into single, high-conviction trial bets rather than diversified platform plays.→
- Jun 30, 2026Flare Therapeutics Raises $85M, Names New CEOFlare Therapeutics closed an $85 million insider-led Series C and named Anna Protopapas CEO, funding its first-in-class ARON-targeting degrader for prostate cancer toward a Phase 1A trial expected in Q3 2026.→
Coverage Timeline
newest firstAll Coverage
FUNDING$391M+ combined across 3 single-trial bets
Biotech VCs Are Betting Big on Single Clinical Trials
Celea Therapeutics' $180M round, Beeline Medicine's $126.3M raise and Flare Therapeutics' $85M financing show late-stage biotech investors concentrating capital into single, high-conviction trial bets rather than diversified platform plays.
FUNDING
Flare Therapeutics Raises $85M, Names New CEO
FUNDING$85M Series C
Flare Therapeutics Raises $85M, Names New CEO
Flare Therapeutics closed an $85 million insider-led Series C and named Anna Protopapas CEO, funding its first-in-class ARON-targeting degrader for prostate cancer toward a Phase 1A trial expected in Q3 2026.
Related Companies
Sources & methodologyshow
Where these figures come from
- GlobeNewswireprimary source1 fact
- BioWorldValue Add VC data1 fact
- Value Add Pulse researchValue Add VC data1 fact
Figures are labelled Reported (a source states it), Estimated, Derived (computed from other facts) or Rumored (in talks / unconfirmed). Rumors never replace a confirmed figure. Each figure keeps its own as-of date; history is preserved rather than overwritten.